GLP-1 Myths Debunked: 15 Things People Get Wrong

This is the most common criticism—and the most absurd. We don't say people with diabetes are "cheating" by taking insulin. We don't accuse people with high blood pressure of taking the "easy way out" with antihypertensives. Obesity is a medical condition with biological drivers. Treating it with medication isn't cheating any more than treating any other chronic disease. The "willpower" model of obesity has been scientifically debunked—genetics, hormones, and neurobiology drive weight far more than character.

This is framed as criticism but is actually just... how chronic disease treatment works. Do you stop blood pressure medication when your BP normalizes? No—the medication is why it's normal. Obesity is chronic. For most people, ongoing treatment produces ongoing benefit. Some people do transition off; most maintain better with continued medication. Neither is wrong—it's individualized medicine.

Partially true—studies show 67% regain within a year of stopping. But this supports continued treatment, not avoiding it entirely. And even with regain, people often don't return to their highest weight. The cardiovascular and metabolic benefits experienced during treatment persist somewhat. Plus: you can restart the medication if you need to.

Access has expanded dramatically. Manufacturer programs offer medications at $299-499/month without insurance. LillyDirect vials work for anyone. Generic semaglutide is arriving internationally with US generics expected 2031-32. Insurance coverage is expanding. Telehealth has made consultations accessible. It's not cheap, but it's increasingly not just for the wealthy.

Thyroid tumors occurred in rodent studies at very high doses over long durations. Human data from large observational studies (including a Nordic cohort of nearly 150,000 patients over 7+ years) has not shown increased thyroid cancer risk. The FDA requires a black box warning due to the animal data, but clinical relevance in humans remains uncertain at best. People with personal or family history of medullary thyroid carcinoma should avoid these medications—for everyone else, the evidence is reassuring.

The FDA investigated and found no evidence of causation. A study of 240,000+ patients found semaglutide associated with 73% LOWER risk of first-time suicidal ideation. Meta-analysis found GLP-1 treatment associated with improved depression scores. The evidence points toward mental health benefit, not harm.

GLP-1 medications have FDA approval for multiple serious medical conditions: obesity, type 2 diabetes, cardiovascular risk reduction, and sleep apnea. The SELECT trial showed 20% reduction in heart attacks and strokes. These are not cosmetic outcomes—they're life-saving medical benefits. Appearance changes are a side effect of treating a disease.

The medication reduces appetite and food noise, but optimal outcomes require lifestyle. Exercise—especially resistance training—is crucial for muscle preservation. Protein intake matters for body composition. The medication is a tool that makes healthy behaviors easier, not a replacement for them.

GLP-1 receptor agonists have been used for diabetes since 2005 (exenatide). Semaglutide has been prescribed since 2017 for diabetes and 2021 for obesity. We have years of real-world data on millions of patients. The SELECT cardiovascular outcomes trial enrolled 17,604 patients over years. These are among the most-studied medications in recent memory.

Clinical trials show 60-75% of weight lost is fat mass. Some lean mass loss occurs (25-40%)—but this happens with ANY significant weight loss. Tirzepatide shows better body composition than semaglutide (~26% lean mass loss). With resistance training and adequate protein, some people actually gain muscle while losing fat. The ratio is similar to other weight loss methods, not worse.

The medications are FDA-approved for BMI ≥30 or BMI ≥27 with comorbidities. Providers prescribe based on medical criteria. Are some people using it "off-label" for smaller amounts of weight? Possibly—but that's between them and their doctor. The existence of optional cosmetic use doesn't diminish the medical necessity for those who truly need it.

Previous weight loss drugs (fen-phen, sibutramine) were withdrawn for causing heart valve damage and cardiovascular events. GLP-1 medications do the opposite—they REDUCE cardiovascular risk by 20%. The mechanism is completely different. These are not stimulants or appetite suppressants in the old sense; they're hormones that already exist in your body.

Weight loss slows and eventually plateaus—this happens with all weight loss methods. It's not the medication "stopping working"; it's your body reaching a new equilibrium. Metabolism adjusts to lower weight. The medication continues to help maintain that lower weight and prevent regain. If weight loss has plateaued and you're below your goal, you may need to titrate to a higher dose or switch medications.

Trial averages are ~15% with semaglutide and ~21% with tirzepatide—but those are averages. Some lose 25%+; some lose 5-10%. About 10-15% of people are "non-responders" who don't lose significant weight. Individual response varies based on genetics, starting point, adherence, lifestyle factors, and more. Manage expectations accordingly.

This was a legitimate concern during 2022-2023 shortages. Manufacturers have dramatically ramped up production; Wegovy and Zepbound now have separate supply streams from their diabetes versions. Compounded semaglutide was restricted in February 2025 specifically because brand-name supply normalized. Supply constraints have largely resolved. Both uses are medically valid.